The Development and Infancy Study (DAISY) is in the emerging field of Behavioural Teratology, exploring the possible effects of in utero exposure to recreational drugs (ecstasy, cannabis, nicotine, etc.) on the subsequent social and cognitive development of the infant. This project is also looking at continued drug use by non-addicted mothers during pregnancy and the possible impact on their health, mental health and interactions with their newborns.
The project was funded by the National Institute on Drug Abuse in the US (Grant: DA14910-01; $3million) and was an international collaborative study between the Drugs and Addictive Behaviours Research Group at UEL and Professor Lynn Singer and colleagues at Case Western Reserve University, in Cleveland, Ohio, and involving Dr Susan Patterson at Imperial College, London.
Singer, L. T., Moore, D. G., Min, M. O., Goodwin, J., Turner, J. J., Fulton, S., & Parrott, A. C. (2016). Motor delays in MDMA (ecstasy) exposed infants persist to 2 years. Neurotoxicology and teratology, 54, 22-28.
Fox, H., Turner, J., Goodwin, J., Moore, D., Parrott, A., Fulton, S., ... & Singer, L. (2016). Developmental outcomes in infants prenatally exposed to Ecstasy (MDMA): a prospective cohort study. International Journal of Psychology, 51.
Singer, L. T., Moore, D. G., Min, M. O., Goodwin, J., Turner, J. J., Fulton, S., & Parrott, A. C. (2015). Developmental outcomes of 3, 4‐methylenedioxymethamphetamine (ecstasy)‐exposed infants in the UK. Human Psychopharmacology: Clinical and Experimental, 30(4), 290-294.
Parrott, A.C., Moore, D.G., Turner, J.J.D., Goodwin, J., Fulton, S., Min, M.O., & Singer, L.T. (2014). MDMA and heightened cortisol: a neurohormonal perspective on the pregnancy outcomes of mothers used 'Ecstasy' during pregnancy. Human Psychopharmacology, 29(1), 1-7. doi:10.1002/hup.2342
Turner, J.J.D., Parrott, A.C., Goodwin, J., Moore, D.G., Fulton, S., Min, M.O., & Singer, L.T. (2014). Psychiatric profiles of mothers who take ecstasy/MDMA during pregnancy: reduced depression one year after giving birth and quitting ecstasy. Journal of Psychopharmacology, 28(1), 55-61. doi:10.1177/0269881113515061
Singer, L.T., Moore, D.G., Fulton, S., Goodwin, J., Turner, J.J.D., Min, M.O., & Parrott, A.C. (2012). Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy. Neurotoxicology and Teratology, 34(3), 303–310. doi:10.1016/j.ntt.2012.02.001
Singer, L.T., Moore, D.G., Min, M.O., Goodwin, J.E., Turner, J.J.D., Fulton, S.E., et al. (2012). One-year outcomes of prenatal exposure to MDMA and other recreational drugs. Pediatrics, 130(3), 407-413. doi:10.1542/peds.2012-0666
Moore, D.G., Turner, J.J.D., Goodwin, J.E., Fulton, S., Singer, L.T., & Parrott, A.C. (2011). In-utero exposure to the popular 'recreational' drugs MDMA (Ecstasy) and methamphetamine (Ice, Crystal): preliminary findings. In Preece & Riley (Eds.), Alcohol drugs and medication in pregnancy. Wiley.
Moore, D.G., Turner, J.D., Parrott, A.C., Goodwin, J.E., Fulton, S.E., Min, M.O., … Singer, L.T. (2009). During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study. Journal of Psychopharmacology, 24(9), 1403-1410. doi:10.1177/0269881109348165